MTOR and neoplasm: Also, the M2327I somatic mutation in the kinase domain of the mTOR was observed in the case of an ATP-competitive inhibitor AZD8055.148 Importantly, the clinical relevance of somatic mutations has been supported when the F2108L mutation was conferred in the patient who relapsed after the treatment of everolimus in anaplastic thyroid carcinoma.149 The mutant tumor cells showed sensitivity to mTOR kinase inhibition.